ArticleJournal of pharmacy & bioallied sciences2024
Elevating Expectations: Vericiguat in Heart Failure with Reduced Ejection Fraction.
Article in Journal of pharmacy & bioallied sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and Safety of Vericiguat in a Real-life Population with Heart Failure after 1 Year of Treatment: The VERITA Study.Cardiac failure review · 2026Article
- Effectiveness and safety of vericiguat in patients with heart failure and reduced ejection fraction: a narrative review of real-world evidence studies.Frontiers in cardiovascular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Heart failure (HF) with reduced ejection fraction (EF) poses high morbidity and mortality. Guidelines Directed Medical Therapy (GDMT) is essential, yet many patients experience significant symptoms. Vericiguat, a soluble guanylate cyclase stimulator, may serve as an adjunctive therapy by enhancing the nitric oxide (NO)-sGC-cyclic guanosine monophosphate (cGMP) pathway. Methods: This observational cohort study involved 100 participants with stage C HF and reduced EF (<40%), divided into two groups: 48 receiving vericiguat plus GDMT and 52 receiving GDMT alone. Primary outcomes included mortality, HF admissions, and changes in EF over 6 months. Results: Mortality rates were lower in the vericiguat group (10.4%) than in GDMT alone (17.3%, Conclusion: Vericiguat may enhance management of stage C HF patients with reduced EF. Larger randomized controlled trials are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.